Market Newsdesk

Muscatine, IA., Sept. 21, 2026 (GLOBE NEWSWIRE) — Executive Summary and Key Takeaways

• The News: For National Ergonomics Month 2026, leading office furnishings manufacturer Allsteel has shared an ergonomics deep-dive, including a step-by-step set-up guide, as well as debunking common ergonomic misconceptions and myths.
• Expert Source: Insights are led by Lauren Gant, PhD, CPE (Certified Professional Ergonomist), Allsteel Senior Workplace Advisory Manager
• Key Philosophy: True ergonomics prioritize dynamic movement, inclusive design, and Work Geometry™ – Allsteel’s human-centric consideration for your posture, fit, and the tools you use to be productive and comfortable.  
• Featured Product: Allsteel’s new award-winning task chair, Levra™ was engineered to meet the four-core ergonomic product design needs: fit, movement, comfort, and intuitiveness.

Muscatine, IA. 
September 21
, 2026 — In honor of National Ergonomics Month in October 2026, leading office furnishings manufacturer Allsteel has released a step-by-step guide to improving your ergonomic set-up. The proper ergonomic set-up not only facilitates a comfortable workday but also helps preserve energy for life outside the office. With insights from Lauren Gant, PhD, CPE (Certified Professional Ergonomist), Allsteel Senior Workplace Advisory Manager, the eight-step, bottom-up desk audit helps individuals achieve a more personalized ergonomic set-up.

Why Are Ergonomics Important for 
Workplace 
Wellness
?
 
Ergonomic principles directly support human wellbeing and organizational health:

• Ergonomics is not about sitting rigidly and still. Dr. Gant emphasizes the importance of movement, noting, “The best posture is your next posture.” Monotonous or sedentary behaviors can become uncomfortable and may have health implications over an extended period of time. Dynamic movement, micro adjustments, and changing postures are all ways to combat static sitting. 
• The impact of ergonomics extends beyond the workday. Dr. Gant explains, “The right ergonomic guidance can have meaningful impacts on how people not only spend their day and feel at work, but also on how they feel at home and spending time with their family or doing the activities that they love.”
• Ergonomics can also support inclusivity and a sense of belonging. Dr. Gant explores the inherently personal nature of ergonomics, noting, “When a workspace is designed to adapt to a person’s unique body, rather than forcing the person to adapt to the furniture, it sends a signal that the space is meant for them.”
• In today’s hybrid working world, ergonomic support can play a role in the overall workplace experience. As employees increasingly expect the office to actively support them and earn the commute, ergonomic comfort can affect not only workplace wellness and performance, but also organizational health.

Step-by-Step Ergonomics “How-To” Guide

1. Seat Height: Adjust your chair height so your feet rest flat on the floor, your knees are bent at approximately 85° to 100°, and your hips are at or slightly above knee level, with your thighs flat or tilted slightly down.
2. Seat Depth: Ensure a 2- to 3-inch gap remains between the front edge of the seat and the back of your knees. This maintains leg circulation and allows your spine to rest properly against the backrest.
3. Lumbar and Recline Tension: Adjust your chair’s lumbar support to actively cradle the curve of your lower back. Set the recline tension to securely support your weight while allowing effortless movement when you shift positions.
4. Armrests and the “Lap Test”: Fold your hands in your lap to find your natural shoulder drop. Adjust your armrest height and width to meet your forearms at that point, with your shoulders relaxed and your elbows near your torso.
5. Worksurface Height: Once your chair is adjusted, pull it up to your desk or worksurface. If your chair is too tall for the worksurface, you may be unable to fit your knees comfortably under the desk. Elevate the desk height with desk raisers or consider using a height-adjustable table. If your chair is too low compared to your worksurface, you may experience awkward postures in the arms, shoulders, and neck. Lower the desk height to coordinate with the chair, consider a height-adjustable table, use a keyboard tray to lower the keyboard and mouse, or elevate the seat height to meet the desk and use a footrest to support the legs and feet.
6. Keyboard and Input Alignment: Keep your keyboard flat and your mouse next to your keyboard. Maintain straight, neutral wrists. Avoid resting wrists on hard table edges, which can restrict blood flow.
7. Monitor Placement: Position your monitor directly in front of you, approximately one arm’s length away, with the top edge of the screen at or slightly below eye level. A monitor arm may also help support proper neck and shoulder postures while viewing.
8. The 20-20-20 Rule: The 20-20-20 rule helps prevent eye strain: every 20 minutes, look at an object 20 feet away for at least 20 seconds.

 What People Get Wrong About Ergonomics – Many overlook or misunderstand key elements of ergonomics.

A few commonly misunderstood areas include:

Myth: There is one “perfect” posture.

Reality: Locking into a single position can cause fatigue or strain. Movement is an essential part of ergonomics.

Myth: Ergonomics stops at the desk.

Reality: Knowledge workers work not only at desks, but also across lounge and collaborative zones or focus rooms. Work Geometry must extend to every zone. For example, a sofa designed for work should have a shallower seat depth than a standard residential sofa to help reduce slumping when using a laptop.

Myth: Physical discomfort is purely mechanical.

Reality: Psychosocial factors, such as high stress, deadlines, or lack of social support, can manifest as physical tension.

Myth: Minimum ADA 
requirements make
 for inclusive design.

Reality: ADA represents the base requirements for accessibility and does not necessarily consider comfort or productivity. True inclusive design is aimed at accommodating different body sizes, ages, cognitive needs, expectations, and experiences.

How Can Office Furniture Meet Higher 
Ergonomic 
Standards
?

Dr. Gant notes, “When we think about what it means for a product to be inherently ergonomic, we focus on four areas: fit, movement, comfort, and intuitiveness.” These core elements are deeply woven into Allsteel’s product offering, particularly in its newest task chair release, Levra™. Levra’s intuitive design focuses on being more human-centric than user-centric, with features such as a first-of-its-kind, patent-pending structural knit back and advanced weight-activated response.

About 
Allsteel
 

Founded in 1912 and headquartered in Muscatine, Iowa, Allsteel designs and manufactures workplace furnishings that elevate performance through thoughtful design. Its portfolio spans architectural systems, private office, seating, and collaborative solutions, enabling cohesive environments across the workplace. Through a co-solutioning approach with dealers and design professionals, Allsteel creates adaptable spaces that support focus, foster connection, and align with evolving workplace strategy while supporting each organization’s culture and priorities. Allsteel operates an Experience Center in Chicago, along with showrooms in Boston, Los Angeles, New York City, San Francisco, and Washington, D.C. Allsteel is part of HNI Corporation, a global family of brands serving commercial and residential markets.  For additional  information, visit or follow Allsteel on  Facebook,  LinkedIn,  Instagram,  Pinterest and YouTube.

Attachment

• Allsteel

NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Innventure, Inc. (NASDAQ: INV). (“Innventure” or the “Company”), on behalf of all investors who purchased Innventure shares between November 17, 2025, and August 13, 2026, inclusive (the “Class Period”).

Investors who purchased Innventure shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for October 27, 2026.

The filed Complaint alleges that Innventure and its executives overstated the likelihood/value of Accelsius’s DarkNX data-center project and, consequently, overstated Accelsius’s expected 2026 revenue and cash flow. Innventure presented the DarkNX agreement as a major, transformative commercial opportunity, while allegedly failing to disclose information indicating that the project was unlikely to materialize.

On August 13, 2026, Innventure said it was suspending its previously communicated 2026 Accelsius revenue and cash-flow expectations. Its Form 10-Q filed with the U.S. Securities and Exchange Commission stated that the DarkNX deployment site was no longer available and the project had been removed from internal bookings.

On this news Inventure fell $1.98 per share, or 55%, from the closing price on August 12, 2026, of $3.60 per share, to close at $1.62 per share, on August 14, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: 
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

– Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 –

– The amended warrants, if exercised in full, together with existing cash balances, expected to provide additional resources to fund launch of CGuard Prime 80 cm following FDA approval –

– No additional warrants issued in connection with the amendments –

MIAMI, Sept. 21, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced that it has entered into amendments with certain of the existing holders of its outstanding Series J and Series K warrants originally issued as part of the Company’s May 2023 private placement financing. The amendments are intended to align the potential exercise of these warrants with the anticipated FDA approval of CGuard Prime 80 cm for transcarotid artery revascularization (“TCAR”) procedures, which the Company continues to anticipate to take place during the fourth quarter of 2026, potentially providing additional capital to support the Company’s commercial plans and ongoing pipeline initiatives.

The amendments apply to approximately 4.8 million shares underlying the Series J warrants and 9.5 million shares underlying the Series K warrants held by participating holders. Pursuant to the amendments, the Company agreed to amend the Series J Warrants with respect to 50% of the shares underlying the participating holders’ Series J Warrants and all of the shares underlying the participating holders’ Series K Warrants to modify (i) the exercise price to $0.7674 per share, representing the Nasdaq Official Closing Price of the Company’s common stock on September 18, 2026, and (ii) the termination date to 5:00 p.m. Eastern time on the earlier of (a) May 15, 2028 and (b) 20 trading days following the Company’s announcement of receipt of FDA approval for the CGuard Prime 80 cm.

The exercise price and termination date with respect to the other 50% of the shares underlying the participating holders’ Series J Warrants remained unchanged, including the original exercise price of $1.3827 per share and the termination trigger events which include the Company’s announcement of FDA approval of the SwitchGuard transcarotid system, which is currently in a Phase III clinical study. All terms and conditions of the Series J Warrants and Series K Warrants held by existing holders that did not elect to enter into the amendments remain unchanged. The amendments do not include the issuance of any additional warrants or any additional shares underlying the existing warrants.

“These amendments align a meaningful portion of our outstanding warrants with a significant near-term regulatory milestone with important commercial implications: the anticipated FDA approval of CGuard Prime 80 cm for TCAR expected later this year,” said Marvin Slosman, Chief Executive Officer of InspireMD. “The expected proceeds, combined with our existing cash resources, will enable us to launch the CGuard Prime 80 into the TCAR market and support other strategic priorities. We appreciate the continued confidence and financial support of many of our major equity holders, as we work to expand the CGuard Prime platform across both the carotid artery stenting (“CAS”) and TCAR markets.”

CGuard Prime 80 cm is designed for use in TCAR procedures, expanding the CGuard Prime platform beyond CAS to both major carotid stenting techniques. The Company estimates that over 35,000 TCAR procedures are performed annually in the United States, representing a doubling of the U.S. addressable market for CGuard Prime. In the CGUARDIANS II pivotal study, CGuard Prime 80 cm demonstrated 100% acute device success and zero major adverse events at 30 days in the first 36 patients evaluated.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Additional information regarding the warrant amendments will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission (“SEC”).

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” “scheduled” or similar words.
In particular, forward-looking statements in this press release include the Company’s expectations regarding potential FDA approval for CGuard Prime 80 cm; ; anticipated gross proceeds from the potential exercise of the Series J Warrants and Series K Warrants and expectations regarding the cash runway of the Company; the Company’s ability to compete effectively in the carotid stenting market and increase adoption of its products; expectations regarding market penetration, commercialization, revenue growth and future operating performance; the anticipated benefits of recent organizational and cost-saving initiatives, including expected annualized savings and improved operational efficiency; and the Company’s strategic priorities, growth plans and future business prospects. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Jeff Warren
LifeSci Advisors
[email protected]
[email protected]

NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Datavault AI Inc. (“Datavault” or the “Company”) (NASDAQ: DVLT) on behalf of investors that purchased or otherwise acquired Datavault securities between September 4, 2024 and October 30, 2025 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Datavault and have suffered losses, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 5, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The complaint alleges, among other things, that on October 31, 2025, Wolfpack Research published a short report on Datavault AI (the “Report”) alleging that Datavault AI was a “stock promotion” that relied on misleading press releases and “empty claims” concerning artificial intelligence, quantum computing, Web 3.0, and data monetization. Additionally, the Complaint alleges that the Report also questioned the activity on the Company’s blockchain marketplace and the Company leadership’s connections with a convicted felon. On this news, Datavault AI’s stock price fell $0.49 per share, or 19.44%, to close at $2.03 per share on October 31, 2025.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/datavault-ai-inc-investor-alert-learn-more-now/

CHANDLER, Ariz., Sept. 21, 2026 (GLOBE NEWSWIRE) — Microchip Technology Incorporated (Nasdaq: MCHP), a broadline supplier of semiconductors committed to making innovative design easier through total system solutions, today announced that it has completed its acquisition of Hailo, a provider of accelerated edge AI processors, vision processors, robotics processors and AI software technologies. The acquisition advances Microchip’s strategy to enable intelligent, connected systems at the edge and expands its ability to deliver complete solutions for Edge AI, machine vision, robotics and Physical AI applications. The terms of the transaction were not disclosed, and the transaction is not expected to have a material impact on Microchip’s financial results.

As artificial intelligence rapidly moves from experimentation to deployment, developers increasingly require solutions that combine AI acceleration, embedded processing, connectivity, security, power efficiency and long-term product support. By bringing together Microchip’s broad embedded systems portfolio with Hailo’s AI and vision technologies, Microchip has broadened its ability to help customers move more quickly from prototype to production.

“AI is becoming a foundational capability across embedded systems, from industrial automation and robotics to intelligent transportation, smart infrastructure and advanced vision applications,” said Steve Sanghi, Chief Executive Officer and Chair of the Board of Microchip Technology. “Hailo strengthens our ability to deliver complete, production-ready platforms that enable customers to deploy intelligent systems at scale. This acquisition expands our product offerings in one of the most important technology transitions in the embedded industry.”

The addition of the Hailo product portfolio expands Microchip’s Edge AI offerings with proven AI accelerators and vision processors supporting computer vision, transformer-based models, multimodal workloads and advanced video analytics.  With this acquisition, Microchip’s portfolio will enable customers to develop intelligent edge systems ranging from low-power smart cameras to high-performance robotics, autonomous machines and next-generation Physical AI platforms.

“The completion of this acquisition is an important enhancement to Microchip’s Edge AI strategy,” said Mark Reiten, Senior Corporate Vice President of Microchip’s Intelligent Compute Business Unit. “Hailo brings industry-leading edge AI acceleration, vision processing expertise and a vibrant developer ecosystem. Combined with Microchip’s embedded processing, FPGA, connectivity, security, analog and power solutions, we can deliver a broader and more complete platform for customers building intelligent edge systems.”

Hailo brings an established ecosystem that includes more than 100 customers, an active developer community exceeding 10,000 users and broad engagement across open-source and AI development platforms. Microchip’s strategy is to continue investing in software tools, development environments and next-generation technologies that simplify AI adoption and accelerate deployment into production applications. 

“Joining Microchip opens exciting opportunities for our customers, partners and developer community,” said Orr Danon, founder and Chief Executive Officer of Hailo. “Microchip’s global reach, customer relationships and embedded systems expertise provide a powerful platform for expanding access to advanced Edge AI and vision technologies.  As part of Microchip, we are well positioned to accelerate innovation and help customers bring intelligent systems to market faster.”

Microchip plans to continue supporting Hailo’s existing product portfolio, software environment and customer engagements while driving future innovation across AI acceleration, vision processing and intelligent edge computing.  Customers will be able to benefit from expanded access to Microchip’s worldwide sales organization, technical support resources and broad portfolio of embedded solutions.

Cautionary Statement:

Cautionary Statement: 

Certain statements in this release, including that the acquisition advances Microchip’s strategy to enable intelligent, connected systems at the edge and expands its ability to deliver complete solutions for Edge AI, machine vision, robotics and Physical AI applications; that the transaction is not expected to have a material impact on Microchip’s financial results; that the transaction has broadened its ability to help customers move more quickly from prototype to production; that AI is becoming a foundational capability across embedded systems, from industrial automation and robotics to intelligent transportation, smart infrastructure and advanced vision applications; that Hailo strengthens our ability to deliver complete, production-ready platforms that enable customers to deploy intelligent systems at scale; that these product offerings are one of the most important technology transitions in the embedded industry; that our expanded portfolio will enable customers to develop intelligent edge systems ranging from low-power smart cameras to high-performance robotics, autonomous machines and next-generation Physical AI platforms; that this acquisition is an important enhancement to Microchip’s Edge AI strategy; that we can deliver a broader and more complete platform for customers building intelligent edge systems; that our strategy is to continue investing in software tools, development environments and next-generation technologies that simplify AI adoption and accelerate deployment into production applications; that joining Microchip opens exciting opportunities for our customers, partners and developer community; that Microchip provides a powerful platform for expanding access to advanced Edge AI and vision technologies; that we are well positioned to accelerate innovation and help customers bring intelligent systems to market faster; that Microchip plans to continue supporting Hailo’s existing product portfolio; that customers will be able to benefit from expanded access to Microchip’s worldwide sales organization, technical support resources and broad portfolio of embedded solutions and that the acquisition further advances Microchip’s vision for enabling intelligent systems at the edge are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause our actual results to differ materially, including, but not limited to: any economic uncertainty due to monetary policy, geopolitical or other issues in the U.S. or internationally, any unexpected fluctuations or weakness in the U.S. and global economies; changes in demand or market acceptance of our products (including Hailo products) and the products of our customers; the mix of inventory we hold and our ability to satisfy short-term orders from our inventory; changes in utilization of our manufacturing capacity and our ability to effectively manage our production levels; competitive developments including pricing pressures; the level of orders that are received and can be shipped in a quarter; changes or fluctuations in customer order patterns and seasonality; our ability to successfully integrate the operations and employees, retain key employees and customers and otherwise realize the expected synergies and benefits of the Hailo acquisition; our ability to obtain a sufficient supply of wafers from third party wafer foundries and the cost of such wafers, the costs and outcome of any current or future tax audit or any litigation involving intellectual property, customers or other issues; disruptions in our business or the businesses of our customers or suppliers due to natural disasters, terrorist activity, armed conflict, war, worldwide oil prices and supply, public health concerns or disruptions in the transportation system; and general economic, industry or political conditions in the United States or internationally. For a detailed discussion of these and other risk factors, please refer to the SEC filings of Microchip including those on Forms 10-K, 10-Q and 8-K.

You can obtain copies of such filings and other relevant documents for free at Microchip’s website (www.microchip.com) or the SEC’s website (www.sec.gov) or from commercial document retrieval services.

Stockholders are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date such statements are made. Microchip undertakes no obligation to publicly update any forward-looking statements to reflect events, circumstances or new information after the date of this press release, or to reflect the occurrence of unanticipated events.

About Microchip Technology

:

Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com. 

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

– First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-

– First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C –

NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, Sept. 21, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, along with partner Menarini Group (“Menarini”), today announced that the European Commission (EC) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination for patients with primary hypercholesterolaemia, both heterozygous familial (“HeFH”) and non-familial or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide.

“The European Commission approval of Ubeslo and Evlarco marks a major milestone for NewAmsterdam as the first regulatory approval of obicetrapib globally, a novel oral therapy, and validates years of work focused on delivering a potential new treatment option for patients who continue to struggle to achieve recommended LDL-C levels despite previously available therapies,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “This first-in-class approval reflects the strength of the clinical evidence supporting obicetrapib, the dedication of our team and partners, and our commitment to addressing one of the largest unmet needs in cardiovascular medicine. Together with Menarini, we look forward to bringing Ubeslo and Evlarco to patients across Europe and building on this important milestone as we advance our vision of making obicetrapib available to patients around the world.”

The European Commission approval follows the positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and is supported by data from NewAmsterdam’s comprehensive clinical development program evaluating obicetrapib, including the Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy versus placebo and approximately 50% with obicetrapib combined with ezetimibe versus placebo, with a tolerability profile comparable to placebo. NewAmsterdam and Menarini continue to advance the clinical development of obicetrapib through multiple ongoing Phase 3 trials, including PREVAIL, a cardiovascular outcomes trial, as well as REMBRANDT and RUBENS.

“This approval represents an important advancement for patients across Europe who require additional LDL-C lowering despite available therapies,” said Elcin Barker Ergun, Chief Executive Officer of Menarini Group. “We are proud to reach this significant achievement alongside NewAmsterdam and look forward to leveraging our well-established commercial capabilities and deep cardiovascular expertise to bring Ubeslo and Evlarco to healthcare providers and eligible patients throughout Europe.”

Under the parties’ licensing agreement, Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization activities throughout the region. NewAmsterdam is entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in the Menarini Territory and up to an additional €833 million upon the achievement of various clinical, regulatory and commercial milestones.

For full details on the approved indications, contraindications, warnings, and precautions please refer to the Summary of Product Characteristics (SmPC) which will be made available on the European Medicines Agency websites at:
https://www.ema.europa.eu/en/medicines/human/EPAR/ubeslo
https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco

About Obicetrapib

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of Major Adverse Cardiovascular Events (“MACE”). The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About Cardiovascular Disease

Cardiovascular disease remains the leading cause of death globally, despite the availability of lipid-lowering therapies (“LLTs”). By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke. In the United States from 2019 through 2022, CVD age-adjusted mortality rates increased by 9%, reversing the trend observed since 2010 and undoing nearly a decade of progress. Despite the availability of high-intensity statins and non-statin LLTs, LDL-C target level attainment remains low, contributing to residual cardiovascular risk, and underscoring a significant clinical need for improved therapeutic regimens. Even with 269 million LLT prescriptions written over the last 12 months, 30 million under-treated US adults are not at their risk-based LDL-C goal, of which 13 million have ASCVD. Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL. In addition to the 30 million under-treated U.S. adults, there are 10 million patients diagnosed with elevated LDL-C who are not taking any LLTs including statins. Beyond LDL-C, additional factors are at play, such as lifestyle choices, tobacco use, and obesity, as well as inflammation, thrombosis, triglyceride levels, elevated Lp(a) levels, and type 2 diabetes.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to build a new standard of care for people living with cardiometabolic disease. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.

About Menarini Group

The Menarini Group, with headquarters in Florence, is present in 140 countries worldwide to date, with $5.5 billion in consolidated turnover and more than 17,000 employees. Menarini’s products are present in the most important treatment areas, including those of cardiometabolic, oncology, gastroenterology, diabetology, pneumology, and anti-inflammatory/analgesic products. Through its commitment to R&D and high-quality manufacturing activities, Menarini continuously contributes to patients’ health worldwide, maintaining the highest quality standards.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. All statements that are not historical facts are hereby identified as forwarding-looking statements for this purposes and include, among others, statements relating to: the therapeutic potential of obicetrapib; expected availability of Ubeslo and Evlarco across Europe; the Company’s licensing agreement with Menarini and entitlement to potential future payments thereunder; the continued advancement of clinical development of obicetrapib through multiple ongoing Phase 3 trials; and other statements regarding the Company’s future operations, prospects, objectives, strategies and other future events. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon management’s current expectations and assumptions. Actual results or events could differ materially and adversely from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various risks, uncertainties and other factors, including, among others: whether projections regarding clinical outcomes will reflect actual results in clinical use of Ubeslo and Evlarco; risks related to the Company’s ability to achieve its business plans, objectives and milestones, including those related to its licensing agreement with Menarini; challenges inherent to the clinical development and launch of new drug products; risks related to the Company’s reliance on third parties; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 18, 2026 and in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as well as in other filings the Company may make with the SEC in the future, which are available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of new information, future events, changed circumstances or otherwise, except as otherwise required by law.

BROADWAY (NCT05142722)
BROOKLYN (NCT05425745)
OCEAN: NCT04770389
PREVAIL (NCT05202509)
REMBRANDT (NCT06305559)
ROSE: NCT04753606
ROSE2: NCT05266586
RUBENS (NCT07219602)
TANDEM (NCT06005597)
TULIP: NCT01970215

Company Contact

Matthew Philippe
P: 1-917-882-7512
[email protected]

Media Contact

Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
[email protected]  

Investor Contact

Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
[email protected]  

Menarini Group Media Contact

Valeria Speroni Cardi
[email protected]

MIAMI, Sept. 21, 2026 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), the data and AI security leader, today announced it has been recognized as a Pace Setter in the Gartner^® Emerging Market Quadrant for AI Application Security – Established Vendors as of September 2026. The report evaluates vendors on their potential to execute and potential for Market Disruption.

Gartner defines the AI application security market as technologies that protect enterprise-developed AI applications and agents by combining security testing, exposure management, and runtime defense to detect, alert on, or block threats. Delivered via SaaS or on-premises technologies, these tools enable cybersecurity and risk teams to manage posture, conduct adversarial testing, and enforce real-time protection of AI applications.

“The more data an AI system can reach, the more valuable and riskier it becomes,” said Rob Sobers, CMO at Varonis. “At Varonis, we’ve built the trust layer that helps organizations to securely connect any AI system to any data source.”

As companies deploy AI applications at scale, these systems are no longer limited to analyzing data: they read, write, modify, and act on it at machine speed. This shift introduces a new class of risk.

Without knowing which systems exist, what they’re doing, or what data they can reach, organizations can’t safely use AI at scale. By integrating AI application visibility and enforcement with the leading Data Security Platform, Varonis gives organizations a way to adopt AI while working to keep risk under control. 

Gartner, Emerging Market Quadrant for AI Application Security
— Established Vendors, By 


Meghan Hollis


, 


Dionisio Zumerle


, 


Dennis Xu


, 


Marissa Schmidt


14 September 2026

Gartner Citation and Disclaimer

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a trademark of Gartner, Inc. and/or its affiliates.

Additional Resources:

• Gartner clients can read the full report.
• Read more on the Varonis blog.
• Learn more about Varonis AI Security.
• Request your Varonis Atlas demo.
• Visit our blog, and join the conversation on LinkedIn and YouTube.

About Varonis

Varonis (Nasdaq: VRNS) secures AI and the data that powers it. The Varonis platform gives organizations automated visibility and control over their critical data wherever it lives and helps ensure safe and trustworthy AI from code to runtime. Backed by 24x7x365 managed detection and response, Varonis gives thousands of organizations worldwide the confidence to adopt AI, reduce data exposure, and stop AI-powered threats.

Investor Relations Contact:
Tim Perz
Varonis Systems, Inc.
646-640-2112
[email protected]

News Media Contact:
Rachel Hunt
Varonis Systems, Inc.
877-292-8767 (ext. 1598)
[email protected]

Purpose-built and designed to help users work smarter, faster and further with seamless experiences that move naturally between phone and laptop. 

News Highlights:

• Keeps users seamlessly connected across their laptop and Android™ phone, enabling tasks, files and apps to move effortlessly between devices while Gemini helps users stay a step ahead
• Moves through the day with an ultra-thin, lightweight 14-inch design, powered by the Snapdragon X Elite platform for advanced performance and long-lasting battery life designed for modern productivity
• Advances purposeful design with recycled metal, post-consumer recycled keyboard components, ocean-bound plastic, recycled/certified-source packaging, and EPEAT Gold with Climate+ certification 
• Elevates collaboration with a 3K OLED touch display, 5MP camera, quad speakers, HP Audio Boost 2.0 and a premium keyboard and touchpad experience

PALO ALTO, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) — Today, HP Inc. (NYSE: HPQ) announced the HP Googlebook 14, a premium laptop designed to bring the best of HP craftsmanship and the performance and efficiency of the Snapdragon® X Elite processorⁱ to the new Googlebook experience. Built for people who move fluidly between their phones, laptops, work, creativity and life, the HP Googlebook 14 combines Google Geminiⁱⁱ, seamless Android phone synchronization and the premium performance and mobility needed to keep up with demanding days.

Designed to work seamlessly with supported Android devicesⁱⁱⁱ, the HP Googlebook 14 helps bring phone and laptop together in a more connected experience. With features like Quick Access^iv and Cast my Apps^v, users can move tasks from phone to laptop, access phone files directly from their laptop’s file browser, open supported phone apps without additional installs, and move naturally between devices throughout the day.

“People don’t think about their day in terms of devices — they think about what they need to get done, where they need to be and whether their technology can keep up,” said Samuel Chang, Senior Vice President and Division President, Consumer Personal Systems at HP Inc. “With the HP Googlebook 14, we’re bringing Google’s intelligent experiences to life through the premium design, performance, and sustainability innovations people expect from HP, while creating a seamless experience between phone and laptop. The result is a laptop that feels more intuitive, connected and responsive to the way people live and work today.”

Premium Design. Connected Workflows. One Seamless Experience.

Today’s professionals move between devices, locations and responsibilities throughout the day. Messages begin on a phone, documents take shape on a laptop, and ideas often move across multiple screens before becoming finished work. For many Android users, the challenge is maintaining momentum from phone to laptop without interruptions. The HP Googlebook 14 was created to make those transitions feel effortless, extending familiar phone experiences to the laptop and making it easier to access the apps, files and content people rely on every day.

Designed for individual creators, independent professionals and small business owners, the HP Googlebook 14 delivers the experiences modern users value most, from intelligent assistance and seamless device connectivity to standout audiovisual experiences and thoughtfully designed sustainability features^vi:

• Keeps phone content close at hand: Designed to work naturally with supported Android devices, users can start tasks on their phone and continue on their laptop, access phone files directly from the file browser through Quick Access and open supported phone apps from their laptop without disrupting their workflow with Cast my Apps.
• Helps users stay a step ahead with Gemini: Built with Gemini at its core, the HP Googlebook 14 helps users stay focused and productive. Features such as Proactive Suggestions^vii, Magic Pointer^viii, and Rambler provide contextual suggestions, surface relevant information and turn messy thoughts to tidy text.
• Moves freely through the day with portability and responsive performance: Powered by Snapdragon X Elite and engineered in an incredibly thin 10.91mm design, the HP Googlebook 14 combines premium portability with up to 19 hours of battery life^ix, A vapor chamber cooling system helps maintain cool, efficient performance, while a compact USB-C® GaN charger makes it easy to stay powered from meetings to home offices and everywhere in between.
• Elevates productivity, creativity and entertainment with immersive audio and visual experiences: From the distinctive Glowbar, which provides an elegant at-a-glance view of battery and charging status even when the device is closed, to a vibrant 3K OLED^x touch display^xi, up to 120Hz variable refresh rate, 5MP IR camera^xii with facial recognition^xiii, support for up to two UHD monitors, and quad speakers with HP Audio Boost 2.0, the HP Googlebook 14 helps users present professionally, collaborate confidently and enjoy rich entertainment experiences wherever they work.
• Reflects purposeful innovation through thoughtful materials: Built with recycled metal^xiv, post-consumer recycled keyboard components^xv, ocean-bound plastic^xvi and sustainably sourced packaging^xvii, the HP Googlebook 14 combines premium design with environmentally conscious materials and EPEAT Gold with Climate+ certification^xviii.

Pricing and Availability

^xix

• The HP Googlebook 14 is expected to be available at HP.com and Best Buy in October for a starting price of $1,199.99.
• Customers will also receive a 12-month Google AI Pro membership at no additional cost^xx, including expanded access to Gemini, Flow and Gemini Notebook, plus 5 TB of cloud storage. In addition, customers can access a curated bundle of apps and services valued at up to $350^xxi, including Adobe Photoshop, CapCut, YouTube Premium and NVIDIA GeForce NOW.

About HP

HP Inc. (NYSE: HPQ) is a global technology leader and creator of solutions that enable people to bring their ideas to life and connect to the things that matter most. Operating in more than 170 countries, HP delivers a wide range of innovative and sustainable devices, services, and subscriptions for personal computing, printing, 3D printing, hybrid work, gaming, and more. For more information, please visit http://www.hp.com.

_______________
ⁱ Multi-core is designed to improve performance of certain software products. Not all customers or software applications will necessarily benefit from use of this technology. Performance and clock frequency will vary depending on application workload and your hardware and software configurations. Qualcomm’s numbering is not a measurement of clock speed. Based on up to 30+ hours of battery life tested by HP using continuous FHD video playback, 1080p (1920×1080) resolution, 200 nits brightness, system audio level as image default, player audio level at 100%, played full-screen from local storage, headphone attached or through speaker (if no audio jack port), wireless on but not connected. Actual battery life will vary depending on configuration and maximum capacity will naturally decrease with time and usage. Features and software that require a NPU may require software purchase, subscription or enablement by a software or platform provider, and third-party software may have specific configuration or compatibility requirements. Potential NPU inferencing performance varies by use, configuration, software and other factors.
ⁱⁱ Available in select languages and to users 18 years or older. Check responses. Internet connection required. Available to users 18 years or older.
ⁱⁱⁱ Android is a trademark of Google LLC. Setup required. Works on supported devices with Android 17 or above.
^iv Initial setup is required. No installations are needed, as apps on your phone are accessible directly on your laptop. Works on supported devices with Android 17 or above.
^v Setup required. Works on supported devices with Android 17 or above.
^vi Feature availability varies by country.
^vii Available in select languages and to users 18 years or older.
^viii Internet connection required. Available to users 18 years or older. Results may vary depending on visual matches and are intended for illustrative purposes only. Sequences may be shortened. Please check responses for accuracy.
^ix Battery life tested by HP using continuous H.264/VP9 1080p video playback at 30 fps and 142 nits brightness. Actual battery life will vary depending on configuration and maximum capacity will naturally decrease with time and usage.
^x All performance specifications represent the typical specifications provided by HP’s component manufacturers; actual performance may vary, either higher or lower. Display measured diagonally
^xi Optional touch capability on select configurations.
^xii Camera resolution refers to the image sensor active pixels. The actual image capture pixels and aspect ratio depend on the app selected.
^xiii Facial recognition supported through Googlebook Face Unlock. Facial recognition is subject to hardware, software, and operating system compatibility. Biometric authentication features require user enrollment and consent. Biometric data used for authentication is managed in accordance with applicable operating system and device security requirements. Internet access may be required for setup.
^xiv Laptops manufactured with recycled metal material in product covers. Percentage of recycled metal varies by product.
^xv Keyboard components contain post-consumer recycled materials.
^xvi Percentage of ocean-bound plastic contained in each component varies by product.
^xvii 100% outer box packaging made from sustainably sourced certified and recycled fibers. Packaging material is 100% sustainability sourced.
^xviii EPEAT registered where applicable, tier levels may vary by country. See www.epeat.net for registration status and tier levels by country.
^xixPricing and availability subject to change without notice.
^xx$239.88 value based on monthly auto-renewal rate, for a limited time only. The Google AI Pro trial offer is available to eligible users with the purchase and activation of an eligible Googlebook on or after October 1, 2026. This offer is limited to users in Australia, Canada, France, Germany, Ireland, New Zealand, the United Kingdom and the United States. Redeem the offer by March 31, 2027 at 11:59pm PT. Google AI Pro will charge $19.99/month or then-current subscription fee for Google AI Pro (minus applied offers plus applicable taxes) after the trial ends. Cancel anytime. Certain AI benefits are only available for those aged 18+. Gemini for Gmail, Docs and more is available in select languages.
^xxiAvailable for a limited time. Terms and conditions apply. See googlebook.com/app-offer-terms-and-conditions for full terms. Value is based on the price of redeeming all subscriptions for the full term.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/33a4428a-157c-4e15-897b-dbf0d239f9fe

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc., (NASDAQ: KTOS) a technology company in the defense, national security and global markets, and GE Aerospace (NYSE: GE) announced a key program milestone with the successful ignition of the GEK800 turbofan cruise missile propulsion system. Recently, the GEK800 Serial Number 1 was tested at the X-58 test facility, igniting successfully. This achievement initiates a new testing campaign and demonstrates a 100 percent success rate for this critical phase of development, keeping the program on schedule.

Recently designated the F143 and designed to meet the defined requirements of the Department of War for long-range, stand-off strike capabilities, the GEK800 represents a significant advancement in affordable, high-performance cruise missile technology. By leveraging modern engineering and cost-effective manufacturing processes, Kratos and GE Aerospace are positioned to deliver substantial capability and value to the warfighter.

“The combined Kratos, GE Aerospace, and Government test team has demonstrated exceptional focus, discipline, and schedule execution,” said Chris Rawlings, Vice President of Kratos’ Defense Engine Portfolio. “This team sets the benchmark for operational efficiency and provides a refreshing reminder that our nation can develop turbine engines affordably and at pace.”

“With this latest milestone, the GEK800 engine continues to demonstrate strong performance and durability,” said Jorge Perez, General Manager of Edison Works Advanced Combat Engines at GE Aerospace. “Our collaboration with Kratos is delivering a highly capable propulsion system designed to meet the demanding requirements of cruise missile applications.”

Delivering Capability to the Department of War and Industry Partners 
For the Department of War and allied defense prime contractors, the GEK800 provides a practical solution to the demand for rapid capability deployment and attritable strike assets. The successful test at X-58 validates the system’s technological architecture, reliability, and readiness for integration. Kratos and GE Aerospace remain focused on providing cruise missile solutions that maintain performance while lowering lifecycle costs, enabling prime contractors to offer highly competitive missile solutions to government procurement programs.

Stacey Rock, President of Kratos’ Turbine Technologies Division, said, “Kratos continues to achieve milestones and accelerate program schedules as we prepare for large volume production of our GEK800 engine to support advanced cruise missile systems.”

GEK800 Tested at Kratos X-58 Test Facility

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b46c295c-8483-402d-a748-e8b158e577fd

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

About GE Aerospace

GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 50,000 commercial and 30,000 military aircraft engines. With a global team of approximately 57,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow, and the future at www.geaerospace.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Kratos Press Contact:

Claire Cantrell
[email protected]

Kratos Investor Information:

877-934-4687
[email protected]

GE Aerospace Press Contact:

Deb Case
[email protected]